Iovance biotherapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Iovance biotherapeutics Contact Number

Contact Iovance Biotherapeutics

2 hours ago Iovance.com Get All

650-260-7120Iovance Biotherapeutics Contact. Our Locations. Headquarters (San Carlos, CA) 999 Skyway Road, Suite 150 San Carlos, CA 94070 Phone: 650-260-7120 Research Facility (Tampa, FL) 3802 Spectrum Blvd. Suite 206 Tampa, FL 33612 Phone: 813-369-5999 Corporate Office (Philadelphia, PA) One Crescent Drive, Suite 303

Website: https://www.iovance.com/contact/

Category: Contact SupportShow more

Iovance Biotherapeutics, Inc. Company Profile San Carlos

1 hours ago Dnb.com Get All

(650) 260-7120999 Skyway Rd Ste 150. San Carlos , CA , 94070-2724. United States. See other locations. Phone. (650) 260-7120. Company Description. Iovance Biotherapeutics, Inc. is located in San Carlos, CA, United States and is part of the Pharmaceutical Manufacturing Industry.

Website: https://www.dnb.com/business-directory/company-profiles.iovance_biotherapeutics_inc.ddf0831bb9e4dea038476473a4ffe7d7.html

Category: Contact NumberShow more

Iovance biotherapeutics, inc. Email Addres & Phone

5 hours ago Lusha.com Get All

Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.

Employees: 101-250

Website: https://www.lusha.com/company/iovance-biotherapeutics-inc/3027cfc1a9675d4c/

Category: Phone NumberShow more

Iovance Biotherapeutics Advancing ImmunoOncology

4 hours ago Iovance.com Get All

Jun 29, 2021 Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET SAN CARLOS, Calif. , June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer

Website: https://www.iovance.com/

Category: Contact NumberShow more

Iovance Biotherapeutics Crunchbase Company Profile & Funding

Just Now Crunchbase.com Get All

Phone Number (212)946-4856. Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product

Founded: 2007
Founder: Manish Singh

Website: https://www.crunchbase.com/organization/lion-biotechnologies

Category: Contact NumberShow more

Iovance Biotherapeutics About Iovance Biotherapeutics

Just Now Iovance.com Get All

Iovance Biotherapeutics is a late-stage oncology company with the potential to bring the first novel autologous T cell therapy to the market for solid tumors in patients with significant unmet needs. We are focused on the development, manufacturing and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL).

Website: https://www.iovance.com/about/about-iovance-biotherapeutics/

Category: Contact NumberShow more

Iovance Biotherapeutics, Inc. Email Format iovance.com

Just Now Rocketreach.co Get All

Iovance Biotherapeutics, Inc. uses 2 email formats, with first '.' last (ex. [email protected]iovance.com) being used 66.7% of the time. Get Verified Emails for Iovance Biotherapeutics, Inc. Employees

Website: https://rocketreach.co/iovance-biotherapeutics-inc-email-format_b449a621fcb00d54

Category: Contact NumberShow more

Iovance Biotherapeutics, Inc. :: Pennsylvania (US

Just Now Opencorporates.com Get All

Free and open company data on Pennsylvania (US) company Iovance Biotherapeutics, Inc. (company number 6881852), PARACORP INCORPORATED Dauphin

Website: https://opencorporates.com/companies/us_pa/6881852

Category: Contact NumberShow more

Iovance Biotherapeutics Management

1 hours ago Iovance.com Get All

Frederick G. Vogt, PhD, Esq. Dr. Vogt joined Iovance Biotherapeutics in September of 2016. He has more than 20 years of experience in the pharmaceutical and biopharmaceutical industries. Prior to joining Iovance, he practiced law at the international firm of Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life

Website: https://www.iovance.com/about/management/

Category: Contact NumberShow more

Iovance Biotherapeutics Inc. (IOVA): The long term

9 hours ago Baxterreport.com Get All

Iovance Biotherapeutics Inc. (IOVA) saw an uptrend of 10.53% in the recent trading with $24.03 being its most recent. The current price level -55.67% lower than the highest price of $54.21 marked by the stock while trading over the past 52-weeks, whereas it is 51.32% higher than the lowest price of $15.88 the company dropped to over past 52-weeks.

Website: https://baxterreport.com/2021/09/16/iovance-biotherapeutics-inc-iova-the-long-term-indicators-on-the-stock-call-for-a-sell-today/

Category: Contact NumberShow more

SEC Filing Iovance Biotherapeutics, Inc.

7 hours ago Ir.iovance.com Get All

SEC File Number: 000-53127. CUSIP Number: 35702Q109 Name and telephone number of person to contact in regard to this notification

Website: https://ir.iovance.com/node/7561/html

Category: Contact NumberShow more

Iovance Biotherapeutics, Inc. (IOVA) Company Profile

5 hours ago Finance.yahoo.com Get All

See the company profile for Iovance Biotherapeutics, Inc. (IOVA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key

Website: https://finance.yahoo.com/quote/IOVA/profile/

Category: Contact NumberShow more

SEC Filing Iovance Biotherapeutics, Inc.

8 hours ago Ir.iovance.com Get All

1. Your name, legal address, and telephone number; 2. The case name and number (In re Iovance Biotherapeutics, Inc. Stockholder Derivative Litigation, No. 1:17-cv-01806-LPS); 3. Proof of being an Iovance stockholder currently and as of December 27, 2019; 4. The date(s) you acquired your Iovance shares; 5. A statement of each objection being

Website: https://ir.iovance.com/node/11401/html

Category: Contact NumberShow more

Iovance Biotherapeutics, Inc. 2021 Annual Meeting

8 hours ago Cstproxy.com Get All

917-262-2373If you wish to submit questions, you can Log Out and try to login again with a control number from your Proxy Card or contact Continental Stock Transfer & Trust Company at 917-262-2373 to do a legal proxy process and receive a temporary number to use.

Website: https://www.cstproxy.com/iovance/2021/

Category: Contact NumberShow more

Iovance Biotherapeutics Research Partners

8 hours ago Iovance.com Get All

Iovance Biotherapeutics is actively seeking partnerships for the development of its products. We believe our novel and versatile technology, promising clinical programs and strong intellectual property make us an attractive partnering candidate. We welcome inquiries from corporations, individuals, and academic institutions.

Website: https://www.iovance.com/about/research-partners/

Category: Contact NumberShow more

SEC Filing Iovance Biotherapeutics, Inc.

8 hours ago Ir.iovance.com Get All

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934. Date of Report (date of earliest event reported): May 15, 2019. IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware. (State of Incorporation) 001-36860. 75-3254381. Commission File Number.

Website: https://ir.iovance.com/node/10756/html

Category: Contact NumberShow more

Iovance Biocom California

8 hours ago Biocom.org Get All

Contact us here: [email protected] About Iovance . Biotech Company Iovance Biotherapeutics is a clinical-stage biotechnology company that focuses on developing and commercializing cancer immunotherapy products. Iovance Biotherapeutics is headquartered in San Carlos, California.

Website: https://www.biocom.org/member/iovance/

Category: Contact NumberShow more

SEC Filing Iovance Biotherapeutics, Inc.

8 hours ago Ir.iovance.com Get All

IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425

Website: https://ir.iovance.com/node/11541/html

Category: Contact NumberShow more

Iovance Biotherapeutics, Inc. in Pennsylvania Company

1 hours ago Bizapedia.com Get All

Iovance Biotherapeutics, Inc. is a Pennsylvania Foreign Business Corporation filed On May 2, 2019. The company's filing status is listed as Active and its File Number is 6881852. The Registered Agent on file for this company is Paracorp Incorporated.

Website: https://www.bizapedia.com/pa/iovance-biotherapeutics-inc.html

Category: Contact NumberShow more

Iovance Biotherapeutics 3802 Spectrum Blvd Tampa, FL

9 hours ago Mapquest.com Get All

(813) 369-5999Iovance Biotherapeutics 3802 Spectrum Blvd Tampa FL 33612. Reviews (813) 369-5999 Website. Menu & Reservations Make Reservations . Please try again later, or report it to our customer service team. Original url: Have questions? NOTE: This URL format is no longer supported. Please update your link, or see our developer link specification for

Website: https://www.mapquest.com/us/florida/iovance-biotherapeutics-358188870

Category: Contact NumberShow more

9. Iovance Biotherapeutics FierceBiotech

2 hours ago Fiercebiotech.com Get All

A number of buyers make sense for Iovance, and Takeda and Gilead Sciences are both names that have been ground out of the rumor mill. (DIGSAU) Iovance Biotherapeutics

Website: https://www.fiercebiotech.com/special-report/iovance-biotherapeutics-top-10-takeover-targets-biopharma

Category: Tech SupportShow more

IOVA.OQ Iovance Biotherapeutics Inc Profile Reuters

1 hours ago Reuters.com Get All

Iovance Biotherapeutics Announces Clinical Data For Ln-145 In Non-Small Cell Lung Cancer. Contact Info. 999 Skyway Rd Ste 150. SAN CARLOS, CA. 94070-2724. United States +1.650.2607120.

Website: https://www.reuters.com/companies/IOVA.OQ

Category: Contact NumberShow more

Jobs with Iovance Biotherapeutics, Inc.

Just Now Biospace.com Get All

Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021. 4/27/2021. Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its …

Website: https://www.biospace.com/employer/400593/iovance-biotherapeutics-inc-/

Category: Contact NumberShow more

IOVA Iovance Biotherapeutics Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Get All

About Iovance Biotherapeutics, … SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN

Website: https://www.biopharmcatalyst.com/company/iova

Category: Contact NumberShow more

Stephen Macrides Email Address & Phone Number Lusha

3 hours ago Lusha.com Get All

Get in touch with Stephen Macrides from Iovance Biotherapeutics, Inc. - direct company email address and phone number. Reach the person you're looking for and other professionals in the same industry. - Lusha

Website: https://www.lusha.com/people/stephen-macrides/deecc9b89d7aa848/

Category: Phone NumberShow more

Patents Assigned to IOVANCE BIOTHERAPEUTICS, INC. Justia

3 hours ago Patents.justia.com Get All

Date of Patent: July 6, 2021. Assignee: Iovance Biotherapeutics, Inc. Inventors: Seth Wardell, James Bender, Michael T. Lotze. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy. Patent number: 11052116. Abstract: The present invention provides improved and/or shortened methods for expanding TILs and

Website: https://patents.justia.com/assignee/iovance-biotherapeutics-inc

Category: Contact NumberShow more

Iovance Biotherapeutics: A Frazier Healthcare Partners

7 hours ago Frazierhealthcare.com Get All

Iovance Biotherapeutics is focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy licensed from the National Cancer Institute for the treatment of refractory metastatic melanoma. Tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor following resection are expanded in

Website: https://www.frazierhealthcare.com/portfolio/iovance-biotherapeutics

Category: Contact NumberShow more

SEC Filing Iovance Biotherapeutics, Inc.

7 hours ago Ir.iovance.com Get All

Exhibit 99.1 . Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results - Company to Host Conference Call at 5:00pm ET Today - SAN CARLOS, CA – August 1, 2017-- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its second quarter 2017 financial

Website: https://ir.iovance.com/node/9441/html

Category: Contact NumberShow more

Iovance Biotherapeutics Gmbh Zug, 6300

2 hours ago Kompany.co.nz Get All

Company Information Iovance Biotherapeutics Gmbh 17040144614 Address:Zug, 6300

Website: https://www.kompany.co.nz/p/ch/17040144614

Category: Contact NumberShow more

Iovance Biotherapeutics Funding, Financials, Valuation

9 hours ago Crunchbase.com Get All

Iovance Biotherapeutics has raised a total of $123M in funding over 2 rounds. Their latest funding was raised on Jun 3, 2016 from a Post-IPO Equity round. Iovance Biotherapeutics is registered under the ticker NASDAQ:IOVA . Iovance Biotherapeutics is funded by 4 investors.

Website: https://www.crunchbase.com/organization/lion-biotechnologies/company_financials

Category: Contact NumberShow more

Iovance Biotherapeutics to Present Clinical Data in Head

8 hours ago Globenewswire.com Get All

Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting. SAN CARLOS, Calif., Oct. 14, …

Website: https://www.globenewswire.com/news-release/2020/10/14/2108771/0/en/Iovance-Biotherapeutics-to-Present-Clinical-Data-in-Head-and-Neck-Cancer-at-Society-for-Immunotherapy-of-Cancer-SITC-35th-Annual-Meeting.html

Category: Contact NumberShow more

Iovance Biotherapeutics (IOVA) Company Profile & Overview

6 hours ago Stockanalysis.com Get All

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment

Website: https://stockanalysis.com/stocks/iova/company/

Category: Contact NumberShow more

Iovance Biotherapeutics Announces Clinical Data Updates

3 hours ago Finance.yahoo.com Get All

Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced new interim data from Cohort 2 in the C-144-01 study

Website: https://finance.yahoo.com/news/iovance-biotherapeutics-announces-clinical-data-210123538.html

Category: Contact NumberShow more

IOVA Stock Iovance Biotherapeutics, Inc. SEC Filings

Just Now Sec.report Get All

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It's lead pipeline candidate, LN-145, is an adoptive cell therapy

Website: https://sec.report/Ticker/IOVA

Category: Contact NumberShow more

Iovance Biotherapeutics Reports Second Quarter and First

2 hours ago Finance.yahoo.com Get All

Expanding Leadership for TIL Cell Therapy in Solid TumorsSAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company

Website: https://finance.yahoo.com/news/iovance-biotherapeutics-reports-second-quarter-200100856.html

Category: Contact NumberShow more

Iovance Biotherapeutics YouTube

3 hours ago Youtube.com Get All

Maria Fardis, President and CEOSan Carlos, CA(NASDAQ: IOVA)Iovance Biotherapeutics is a clinical-stage biotechnology company focused on the development of ca

Website: https://www.youtube.com/watch?v=TMjRHYBvwOw

Category: Contact NumberShow more

IOVANCE BIOTHERAPEUTICS, INC. : Shareholders Board Members

4 hours ago Marketscreener.com Get All

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.

Website: https://www.marketscreener.com/quote/stock/IOVANCE-BIOTHERAPEUTICS-36879287/company/

Category: Contact NumberShow more

Can Iovance Biotherapeutics TILt the balance in favour of

6 hours ago Pharmaceutical-technology.com Get All

The results from Iovance’s pivotal Phase II trial (NCT02360579) with Stage III/IV melanoma patients are certainly impressive. Patients who progress on either PD-1 or BRAF/MEK inhibitors are notoriously difficult to treat. In this Phase II pivotal trial, the mean number of therapies prior to trial enrollment was 3.3.

Website: https://www.pharmaceutical-technology.com/comment/iovance-biotherapeutics-til-therapy/

Category: Contact NumberShow more

Artisan Partners Remains ‘Patient’ in Iovance

6 hours ago Finance.yahoo.com Get All

Iovance Biotherapeutics, Inc. is a San Carlos, California-based biopharmaceutical startup with a $3.8 billion market capitalization. IOVA delivered a -45.91% return since the beginning of the year

Website: https://finance.yahoo.com/news/artisan-partners-remains-patient-iovance-171126168.html

Category: Contact NumberShow more

Why Iovance Biotherapeutics Soared 40% In June The

8 hours ago Fool.com Get All

Shares of Iovance Biotherapeutics ( NASDAQ:IOVA) gained 40.1% last month, according to numbers from S&P Global Market Intelligence. The move, largely driven by an update on a key clinical trial

Website: https://www.fool.com/investing/2021/07/08/why-iovance-biotherapeutics-soared-40-in-june/

Category: Contact NumberShow more

IOVA Graham Number Iovance Biotherapeutics GuruFocus.com

8 hours ago Gurufocus.com Get All

For the Biotechnology industry, Iovance Biotherapeutics's Graham Number, along with its competitors' market caps and Graham Number data, can be viewed below: * Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot

Website: https://www.gurufocus.com/term/grahamnumber/IOVA/Graham-Number/Iovance%20Biotherapeutics

Category: Contact NumberShow more

Iovance Biotherapeutics (IOVA) Stock Price, Quote & News

8 hours ago Stockanalysis.com Get All

Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021. SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i

Website: https://stockanalysis.com/stocks/iova/

Category: Contact NumberShow more

Iovance Biotherapeutics, Inc. (IOVA) Balance Sheet Yahoo

1 hours ago Finance.yahoo.com Get All

Get the annual and quarterly balance sheet of Iovance Biotherapeutics, Inc. (IOVA) including details of assets, liabilities and shareholders' equity. Contact Us; U.S. markets close in 1 hour

Website: https://finance.yahoo.com/quote/IOVA/balance-sheet/

Category: Contact NumberShow more

IOVANCE BIOTHERAPEUTICS, INC. : IOVA Stock Price

6 hours ago Marketscreener.com Get All

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.

Website: https://www.marketscreener.com/quote/stock/IOVANCE-BIOTHERAPEUTICS-36879287/

Category: Contact NumberShow more

Iovance Biotherapeutics: Buy the Dip? The Motley Fool

2 hours ago Fool.com Get All

12.29.235

Website: https://www.fool.com/investing/2019/08/27/iovance-biotherapeutics-buy-the-dip.aspx

Category: Contact NumberShow more

Scrip

9 hours ago Scrip.pharmaintelligence.informa.com Get All

(212) 520-2765Please contact Sales at: (212) 520-2765 or email [email protected] Latest From Iovance Biotherapeutics, Inc. Eight Oncology Drug Launches Expected In 2022 – Solid Tumors

Website: https://scrip.pharmaintelligence.informa.com/companies/3367

Category: Contact NumberShow more

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Is 35.81% Above

Just Now Marketingsentinel.com Get All

Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s traded shares stood at 1.34 million during the last session, with the company’s beta value hitting 0.83. At the close of trading, the stock’s price was $24.74, to imply an increase of 3.08% or $0.74 in intraday trading. The IOVA share’s 52-week hi

Website: https://marketingsentinel.com/2021/06/24/iovance-biotherapeutics-inc-nasdaqiova-is-35-81-above-its-52-week-low-but-will-it-continue-to-rise/

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is iovance Biotherapeutics?

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.

Who is the founder and CEO of iovance?

Dr. Graf Finckenstein is a physician-scientist with decades of experience in clinical medicine, laboratory cancer research, and drug development in the biopharmaceutical industry.

What kind of clinical trials is iovance in?

IOVANCE is recruiting patients in four Phase 2 clinical trials to assess the efficacy and safety of autologous cell therapies for treatment of patients with cancer. C-145-04 is a multicenter clinical trial in patients with metastatic cervical cancer at various sites in the U.S. and Europe.

How does iovance extract T lymphocytes from the body?

Using that platform, Iovance extracts T lymphocytes from the body, boosting their growth in the lab and reinfusing them back into the patient, following a similar approach to current CAR-T therapies.

Popular Brands

Intel
Icbc
Imcd
Iqvia
Isbank
Idex
Ing
Intuit
Itc
Ipg
Icade